Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLYB212 in pregnant women at risk for HPA-1a alloimmunization
NCT06435845Phase 2Terminated
- Sponsor
- Rallybio
- Start
- Nov 2024
- Primary completion
- Oct 2025
- Countries
- 3
01
Overview
A Phase 2 trial of RLYB212 in fetal and neonatal alloimmune thrombocytopenia (FNAIT), sponsored by Rallybio. Started Nov 2024; status: terminated.
02
Drugs
RLYB212
03
Conditions
fetal and neonatal alloimmune thrombocytopenia (FNAIT)
Beyond the preview
Go deeper on NCT06435845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435845.